ARGATROBAN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for argatroban and what is the scope of patent protection?
Argatroban
is the generic ingredient in four branded drugs marketed by Amneal Pharms Co, Caplin, Endo Operations, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma Pharm Co Ltd, Hospira, Mylan Institutional, Sandoz, Teva Pharms Usa, Cipla, Accord Hlthcare, and Eugia Pharma Speclts, and is included in sixteen NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Argatroban has seven patent family members in five countries.
There are eleven drug master file entries for argatroban. Eleven suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for ARGATROBAN
International Patents: | 7 |
US Patents: | 2 |
Tradenames: | 4 |
Applicants: | 13 |
NDAs: | 16 |
Drug Master File Entries: | 11 |
Finished Product Suppliers / Packagers: | 11 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 34 |
Patent Applications: | 245 |
Drug Prices: | Drug price trends for ARGATROBAN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARGATROBAN |
What excipients (inactive ingredients) are in ARGATROBAN? | ARGATROBAN excipients list |
DailyMed Link: | ARGATROBAN at DailyMed |
Recent Clinical Trials for ARGATROBAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Veralox Therapeutics | Phase 2 |
Celerion | Phase 1 |
Veralox Therapeutics | Phase 1 |
Generic filers with tentative approvals for ARGATROBAN
Applicant | Application No. | Strength | Dosage Form |
⤷ Subscribe | ⤷ Subscribe | 250MG/250ML | INJECTABLE; INJECTION |
⤷ Subscribe | ⤷ Subscribe | 100MG | INJECTABLE; INJECTION |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for ARGATROBAN
Drug Class | Anti-coagulant Direct Thrombin Inhibitor |
Mechanism of Action | Thrombin Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ARGATROBAN
Paragraph IV (Patent) Challenges for ARGATROBAN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ARGATROBAN IN SODIUM CHLORIDE | Injection | argatroban | 1 mg/mL, 50 mL vials | 022434 | 1 | 2011-12-16 |
ARGATROBAN | Injection | argatroban | 100 mg/mL, 2.5 mL vials | 020883 | 1 | 2007-09-24 |
US Patents and Regulatory Information for ARGATROBAN
Expired US Patents for ARGATROBAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sandoz | ARGATROBAN | argatroban | INJECTABLE;INJECTION | 020883-001 | Jun 30, 2000 | 5,214,052 | ⤷ Subscribe |
Sandoz | ARGATROBAN | argatroban | INJECTABLE;INJECTION | 020883-001 | Jun 30, 2000 | 5,925,760 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ARGATROBAN
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2083823 | PRÉPARATION SANS ALCOOL D'ARGATROPAN (ALCOHOL FREE FORMULATION OF ARGATROBAN) | ⤷ Subscribe |
Canada | 2669727 | PREPARATION SANS ALCOOL D'ARGATROPAN (ALCOHOL FREE FORMULATION OF ARGATROBAN) | ⤷ Subscribe |
Japan | 5624766 | ⤷ Subscribe | |
China | 101516370 | Alcohol free formulation of argatroban | ⤷ Subscribe |
Japan | 2010504971 | ⤷ Subscribe | |
World Intellectual Property Organization (WIPO) | 2008039473 | ⤷ Subscribe | |
World Intellectual Property Organization (WIPO) | 2008045410 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
ARGATROBAN Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.